Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 324-329

  Vassalou, Helen ^a   Stathopoulos, Efstathios ^b   Fiolitaki, Georgia ^b   Koutsopoulos, Anastasios ^b   Voutsina, Alexandra ^a   Georgoulias, Vassilis ^a,b   Mavroudis, Dimitris ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

ERCC1; Front line chemotherapy; Immunohistochemistry; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ERCC1; FRONT-LINE CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PLATINUM-BASED CHEMOTHERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887024957     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.001     Document Type: Article

References (41)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
3. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
4. Molina J.R., Adjei A.A., Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 2006, 130(4):1211-1219.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
6. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70.
7. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998, 27(1-3):187-201.
8. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478(1-2):23-43.
9. Altaha R., Liang X., Yu J.J., Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004, 14(6):959-970.
10. Gazdar A.F. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007, 356(8):771-773.
11. Li Q., Ding L., Yu J.J., Mu C., Tsang B., Bostick-Bruton F., et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998, 13(5):987-992.
12. Li Q., Yu J.J., Mu C., Yunmbam M.K., Slavsky D., Cross C.L., et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000, 20(2A):645-652.
13. Papay J., Sapi Z., Egri G., Gyulai M., Szende B., Losonczy G., et al. Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1. Pathol Oncol Res 2009, 15(3):445-450.
14. Handra-Luca A., Hernandez J., Mountzios G., Taranchon E., Lacau-St-Guily J., Soria J.C., et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007, 13(13):3855-3859.
15. Lee H.W., Hwang Y.H., Han J.H., Choi J.H., Kang S.Y., Jeong S.H., et al. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 2010, 46(3):209-213.
16. Kim M.K., Cho K.J., Kwon G.Y., Park S.I., Kim Y.H., Kim J.H., et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008, 14(13):4225-4231.
17. Kim M.K., Cho K.J., Kwon G.Y., Park S.I., Kim Y.H., Kim J.H., et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008, 44(1):54-60.
18. Steffensen K.D., Waldstrom M., Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009, 19(5):820-825.
19. Steffensen K.D., Waldstrom M., Jeppesen U., Brandslund I., Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 2008, 18(4):702-710.
20. Lee H.W., Han J.H., Kim J.H., Lee M.H., Jeong S.H., Kang S.Y., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008, 59(1):95-104.
21. Hwang I.G., Ahn M.J., Park B.B., Ahn Y.C., Han J., Lee S., et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113(6):1379-1386.
22. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007, 98(9):1336-1343.
23. Kang C.H., Jang B.G., Kim D.W., Chung D.H., Kim Y.T., Jheon S., et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010, 68(3):478-483.
24. Azuma K., Sasada T., Kawahara A., Hattori S., Kinoshita T., Takamori S., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009, 64(3):565-573.
25. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64(3):326-333.
26. Shanbhogue A.K., Karnad A.B., Prasad S.R. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010, 34(4):479-484.
27. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
28. Lee H.W., Choi Y.W., Han J.H., Kim J.H., Jung J.H., Jeong S.H., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009, 65(3):377-382.
29. Ota S., Ishii G., Goto K., Kubota K., Kim Y.H., Kojika M., et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64(1):98-104.
30. Holm B., Mellemgaard A., Skov T., Skov B.G. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009, 27(26):4254-4259.
31. Ikeda S., Takabe K., Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009, 59(12):863-867.
32. Wang X., Zhao J., Yang L., Mao L., An T., Bai H., et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 2010, 27(2):484-490.
33. Jeong S.H., Jung J.H., Han J.H., Kim J.H., Choi Y.W., Lee H.W., et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 2010, 68(2):288-294.
34. Vilmar A.C., Santoni-Rugiu E., Sorensen J.B. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, 21(9):1817-1824.
35. Reynolds C., Obasaju C., Schell M.J., Li X., Zheng Z., Boulware D., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27(34):5808-5815.
36. Das M., Riess J.W., Frankel P., Schwartz E., Bennis R., Hsieh H.B., et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012, 77(2):421-426.
37. Taillade L., Penault-Llorca F., Boulet T., Fouret P., Michiels S., Taranchon E., et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007, 18(6):1043-1050.
38. Gomez-Roca C., Raynaud C.M., Penault-Llorca F., Mercier O., Commo F., Morat L., et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009, 4(10):1212-1220.
39. Kang C.H., Jang B.G., Kim D.W., Chung D.H., Kim Y.T., Jheon S., et al. Differences in the expression profiles of excision repair crosscomplementation group 1, X-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol 2009, 4(11):1307-1312.
40. Ma D., Baruch D., Shu Y., Yuan K., Sun Z., Ma K., et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol 2012, 12(November):88.
41. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013, 368(March (12)):1101-1110.